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Volume 58, Number 4 Abstracts 1147Conclusions: The protective effects of estrogen on AAAs can be
divided into central and peripheral estrogen effects depending on the site
of estrogen synthesis. Central estrogen synthesis from the ovaries accounted
for the majority of the protective effects of estrogen, while peripheral
estrogen conversion accounted for only one-third of the effect. These ﬁnd-
ings may explain the increased incidence of AAAs in postmenopausal
women lacking central estrogen synthesis.
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Objectives: Recent randomized controlled trials (RCTs) like ASTRAL
and STAR show no clear beneﬁt of endovascular renal artery intervention
(ERAI) on renovascular disease progression or blood pressure control
compared with medical treatment. We wanted to analyze their impact on
the national trends in ERAI and open renal artery interventions (ORAI).
Methods: Nationwide Inpatient Sample was analyzed from 2007 to
2010 to identify patients undergoing ERAI or ORAI on yearly basis around
the publications of RCTs. Patient demographics, comorbidities, length of
stay, in hospital complications, and mortality were compared among
ERAI and ORAI patients using c2 and independent t-test.
Results: 71,396 patients underwent renal artery interventions from
2007 to 2010. Sixty-nine thousand eight-hundred and four (97.7%)
ERAI and 1421 (2%) ORAI. One-hundred seventy-one (0.3%) had both
and were excluded. ERAI patients were older (71.5 6 10.8 vs 64.6 6
12.3 years; P < .001) and had higher incidence of comorbidities including
diabetes mellitus (32.2% vs 13.9%; P < .001), hypertension (45.5% vs
39.1%; P < .001), coronary artery disease (57.4% vs 28.1%; P <.001),
and obesity (5.5% vs 0.1%; P < .001). ORAI patients had higher incidence
of smoking (26.2% vs 15.6%; P < .001) and chronic obstructive pulmonary
disease (24.1% vs 19.2%; P < .001). The number of ERAI decreased by
53.5% (22,824 vs 10,593) from 2007 to 2010. This decline was progressive
with 10.3% (22824 vs 20482) decrease from 2007 to 2008, 22.3% (20482
vs 15905) from 2008 to 2009 and the most signiﬁcant decrease of 33.4%
(15905 vs 10593) from 2009 to 2010 corresponded with the publication
of ASTRAL and STAR. In contrast to the sharp decline in ERAI, only
15.7% (343 vs 289) decline was seen in ORAI from 2007 to 2010.
ORAI patients had longer hospital stay and higher in hospital complications
and mortality (Table).
Conclusions: There is a progressive decline in ERAI nationally corre-
sponding with publication of recent RCTs. The trend is signiﬁcant even
with all limitations including selection bias in these trials. There is a great
need and anticipation of a better designed RCT to look at the efﬁcacy of
ERAI for renal artery stenosis before abandoning it.
Table. Yearly national trends and comparison of endovascular and open
renal artery interventions
ERAI ORAI P valueIndex year
2007 22824 (32.7%) 343 (24.1%)
2008 20482 (29.3%) 421 (29.6%)
2009 15905 (22.8%) 368 (25.9%)
2010 10593 (15.2%) 289 (20.3%)Mean age, years 71.5 6 10.8 64.6 6 12.3 <.001
Mean hospital stay, days 4.1 6 5.4 9.9 6 7.6 <.001
In-hospital mortality 596 (0.9%) 109 (7.7%) <.001
Hemorrhage 785 (1.1%) 46 (3.2%) <.001
Pneumonia 45 (0.1%) 35 (2.3%) <.001
Cardiac complication 543 (0.8%) 94 (6.6%) <.001
Renal failure 253 (0.4%) 70 (4.9%) <.001
Infection 143 (0.2%) 25 (1.8%) <.001Scientiﬁc Session II: Dialysis
Elderly Patients Started on Hemodialysis with a Tunneled Dialysis
Catheter Have Similar Long-Term Survival after Arteriovenous
Fistula or Arteriovenous Graft Placement
Theodore H. Yuo, Rabih A. Chaer, Ellen D. Dillavou, Luke K. Marone,
Michel S. Makaroun. University of Pittsburgh, Pittsburgh, PaObjectives: SVS guidelines suggest dialysis through arteriovenous
ﬁstula (AVF) is associated with a survival advantage over arteriovenous graft
(AVG). However, AVF often require months to become functional,
increasing tunneled dialysis catheter (TDC) use in patients starting hemodi-
alysis (HD) with TDC. We sought to compare survival in patients with end-
stage renal disease (ESRD) based on HD access type.
Methods: Using US Renal Data System databases, we identiﬁed inci-
dent HD patients in 2005 and followed them through 2008. Initial access
type was assessed using USRDS data collection forms. Attempts at AVF and
AVG creation were identiﬁed by current procedural terminology codes.
Patients were divided into groups based on whether an attempt at AVF
or AVG was undertaken within 3 months after initiation of HD. Log-
rank tests were used for pairwise survival comparisons, stratiﬁed by age.
The primary outcome was vital status.
Results: We analyzed 46,672 patients who started HD in 2005 and
survived at least 3 months. TDC was the initial access for 80% of patients;
52% were 65 years or older. At 1 year, patients starting HD with AVF
had improved survival compared with patients who initiated HD through
TDC (88% vs 76%; P < .001) or through AVG (88% vs 83%; P < .001).
In patients over 65 who initiate HD with TDC, creation of AVF and
AVG are associated with identical survival (P ¼ NS), with both signiﬁcantly
better than continued HD through TDC (P < .001) (Fig).
Conclusions: Initiation of HD through AVF is associated with
improved survival compared with AVG and TDC, but is a small fraction
of ESRD patients. In patients over 65 that initiate HD through TDC, crea-
tion of AVF is not superior to AVG in terms of survival.
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Objectives: We have previously investigated the use of ASCs differen-
tiated toward an endothelial cell lineage in the creation of a tissue-engi-
neered vascular graft. In this study, we report progress toward adding
a medial layer to the artiﬁcial artery, composed of the same autologous
ASCs, but differentiated toward a smooth muscle cell (SMC) lineage.
Such a layer may improve the strength, endothelial function, and anti-
inﬂammatory properties of the conduit.
Methods: ASC isolated from vascular patients via peri-umbilical lipo-
suction were differentiated toward SMC lineage using transforming growth
factor-b1. Phenotypic evaluation included polymerase chain reaction and
immunoblot for SMC-speciﬁc markers (a-actin, calponin, myosin heavy
chain). Contractile function was evaluated using a collagen lattice gel. SIS
vascular scaffolds (Cook Biotech, Inc, West Lafayette, Ind) seeded with
ASC-SMC (outside surface) and ASC- endothelial cell (luminal surface)
were ﬂow conditioned over 5 days within a bioreactor (up to 9 dynes,
120% stretch). Cell morphology and retention was evaluated using confocal
microscopy.
Results: ASC newly acquired SMC message and protein markers
following in vitro culture in TGF-b1 medium, although myosin heavy chain
expression was only variably expressed after 2 weeks of differentiation,
